表在性静脈血栓症、静脈性血栓塞栓症の合併高率 
                 
                文献:Decousus H et al. Superficial   Venous Thrombosis and Venous Thromboembolism: A Large, Prospective Epidemiologic   Study. Ann Intern Med. 2010;152(4):218-24 
                表在性静脈血栓症患者844名を対象に、静脈性血栓塞栓症の罹患率・リスクを前向きコホート研究で調査。登録時に210名(24.9%)の患者が静脈性血栓塞栓症を合併しており、合併がない患者でも、3カ月間の追跡期間中に600名中58名(10.2%)で血栓塞栓症の合併が見られた。 
                Superficial Venous Thrombosis and Venous   Thromboembolism
                A Large, Prospective Epidemiologic Study
                
                  
                    - Herve   Decousus, MD;   
                    
 - Isabelle   Quere, MD;   
                    
 - Emilie   Presles, MD;   
                    
 - Francois   Becker, MD;   
                    
 - Marie-Therese   Barrellier, MD;   
                    
 - Myriam   Chanut, MD;   
                    
 - Jean-Luc   Gillet, MD;   
                    
 - Herve   Guenneguez, MD;   
                    
 - Christine   Leandri, MD;   
                    
 - Patrick   Mismetti, MD, PhD;   
                    
 - Olivier   Pichot, MD;   
                    
 - Alain   Leizorovicz, MD; and   
                    
 - for the POST   (Prospective Observational Superficial Thrombophlebitis) Study Group*
 
                   
                  + Author Affiliations 
                  
                    - 
                        
                          From University Hospital, Saint-Etienne, France; Saint Eloi University   Hospital, Montpellier, France; University Hospital, Geneva, Switzerland;   University Hospital, Caen, France; Vascular Medicine, Aubenas, France; Vascular   Medicine, Bourgoin-Jailleu, France; Megival Clinic, Saint-Aubin-sur-Scie,   France; Vascular Medicine, Annonay, France; Vascular Medicine, Grenoble, France;   and UMR 5558, Lyon, France.
                      
                    
 
                   
                 
                
                  Abstract
                  Background: Superficial venous thrombosis (SVT) is   perceived to have a benign prognosis.  
                  Objective: To assess the prevalence of venous   thromboembolism in patients with SVT and to determine the 3-month incidence of   thromboembolic complications.  
                  Design: National cross-sectional and prospective   epidemiologic cohort study. (ClinicalTrials.gov registration number:   NCT00818688)  
                  Setting: French office- and hospital-based vascular   medicine specialists.  
                  Patients: 844 consecutive patients with symptomatic   SVT of the lower limbs that was at least 5 cm on compression ultrasonography.  
                  Measurements: Incidence of venous thromboembolism and   extension or recurrence of SVT in patients with isolated SVT at presentation.  
                  Results: Among 844 patients with SVT at inclusion   (median age, 65 years; 547 women), 210 (24.9%) also had deep venous thrombosis   (DVT) or symptomatic pulmonary embolism. Among 600 patients without DVT or   pulmonary embolism at inclusion who were eligible for 3-month follow-up, 58   (10.2%) developed thromboembolic complications at 3 months (pulmonary embolism,   3 [0.5%]; DVT, 15 [2.8%]; extension of SVT, 18 [3.3%]; and recurrence of SVT, 10   [1.9%]), despite 540 patients (90.5%) having received anticoagulants. Risk   factors for complications at 3 months were male sex, history of DVT or pulmonary   embolism, previous cancer, and absence of varicose veins.  
                  Limitation: The findings are from a specialist   referral setting, and the study was terminated before the target patient   population was reached because of slow recruitment.  
                  Conclusion: A substantial number of patients with SVT   exhibit venous thromboembolism at presentation, and some that do not can develop   this complication in the subsequent 3 months.  
                  Primary Funding Source: GlaxoSmithKline,   sanofi-aventis, and the Ministere Francais de la Sante et des Sports (Programme   Hospitalier de Recherche Clinique).  
                 
                
                  Article and Author Information
                  
                    - 
                      
Note: This work was presented as 2 abstracts at the   Congress of the International Society of Thrombosis and Haemostasis, Geneva,   Switzerland, 6-12 July 2007 (J Thromb Haemost. 2007;5 (supp 1):abstracts O-S-OR9   and P-S 600).  
                     - 
                      
Acknowledgment: The authors thank Zohra Akkal for   her assistance in coordinating the study.  
                     - 
                      
Grant Support: By GlaxoSmithKline, sanofi-aventis,   the Ministere Francais de la Sante et des Sports (Programme Hospitalier de   Recherche Clinique), the Societe Francaise de Medecine Vasculaire, and the   Societe Francaise de Phlebologie.  
                     - 
                      
Potential Conflicts of Interest: Disclosures can be   viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M09-0686.  
                     - 
                      
Reproducible Research Statement: Study protocol,   statistical code, and data set: Available from Dr. Decousus (e-mail, herve.decousus@chu-st-etienne.fr)  
                     - 
                      
Requests for Single Reprints: Herve Decousus, MD,   Service de Medecine et Therapeutique, Groupe de recherche sur la thrombose (EA   3065), Centre d'Investigation Clinique CIE3 (INSERM/DHOS), Hopital Nord, CHU   Saint-Etienne, 42055 Saint-Etienne Cedex, France.  
                     - 
                      
Current Author Addresses: Dr. Decousus: Service de   Medecine et Therapeutique, Hopital Nord, Batiment A, Niveau 0, 42055   Saint-Etienne Cedex 2, France.  
                     - 
                      
Dr. Quere: CHU de Montpellier, Service des Maladies Vasculaires,   Hopital Saint-Eloi, 80 rue Fliche, 34295 Montpellier Cedex 5, France.  
                     - 
                      
Dr. Presles: CHU de Saint-Etienne, Batiment Recherche, Hopital Nord,   42055 Saint-Etienne Cedex 2, France. 
                     - 
                      
Dr. Becker: 40 chemin Favrands, 74400 Chamonix, France. 
                     - 
                      
Dr. Barrellier: Laboratoire des Explorations Fonctionnelles, Niveau   01, CHU Cote de Nacre, 14033 Caen Cedex, France. 
                     - 
                      
Dr. Chanut: Medecine Vasculaire, Le Clos de Bellande, Rue Denis   Papin, 07200 Aubenas, France. 
                     - 
                      
Dr. Gillet: Medecine Vasculaire, 51 Bis avenue Professeur Tixier,   38300 Bourgoin-Jaillieu, France. 
                     - 
                      
Dr. Guenneguez: Clinique Megival, 1328 avenue Maison Blanche, 76550   Saint-Aubin-sur-Scie, France. 
                     - 
                      
Dr. Leandri: Medecine Vasculaire, Les Domaines de la Gare, 07100   Annonay, France. 
                     - 
                      
Dr. Mismetti: URCIP, Batiment Recherche, Hopital Nord, 2055   Saint-Etienne Cedex 2, France. 
                     - 
                      
Dr. Pichot: Centre de Medecine Vasculaire, 7 rue Lesdiguieres, 38000   Grenoble, France. 
                     - 
                      
Dr. Leizorovicz: Service de Pharmacologie Clinique, Faculte Laennec,   rue Guillaume Paradin, BP 8071, 69376 Lyon Cedex 8, France. 
                     - 
                      
Author Contributions: Conception and design: H.   Decousus, I. Quere, F. Becker, J.L. Gillet, P. Mismetti, O. Pichot.  
                     - 
                      
Analysis and interpretation of the data: H. Decousus, I. Quere, F.   Becker, P. Mismetti, A. Leizorovicz. 
                     - 
                      
Drafting of the article: H. Decousus, P. Mismetti, A.   Leizorovicz. 
                     - 
                      
Critical revision of the article for important intellectual content:   H. Decousus, I. Quere, F. Becker, J.L. Gillet, P. Mismetti, O. Pichot, A.   Leizorovicz.  
                     - 
                      
Final approval of the article: H. Decousus, I. Quere, F. Becker, M.T.   Barrellier, M. Chanut, H. Guenneguez, C. Leandri, P. Mismetti, O. Pichot, A.   Leizorovicz.  
                     - 
                      
Provision of study materials or patients: I. Quere, M. Chanut, J.L.   Gillet, H. Guenneguez, C. Leandri, O. Pichot. 
                     - 
                      
Statistical expertise: E. Presles. 
                     - 
                      
Obtaining of funding: A. Leizorovicz. 
                     - 
                      
Administrative, technical, or logistic support: H. Decousus, I.   Quere, E. Presles, M.T. Barrellier, A. Leizorovicz. 
                     - 
                      
Collection and assembly of data: A. Leizorovicz. 
                     - 
                      
* For a list of participating committees and   investigators, see the Appendix.  
                     
                   
                  |